SCHEMBL1127394

SCHEMBL1127394

CCC(C)OC(=O)C(C(=O)O)C(=O)C(Cc1ccc(Cl)cc1)c1ccccn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MME P08473 1/20 0.39
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
GPR119 Q8TDV5 1/20 0.38
BLM P54132 1/20 0.37
LMNA P02545 1/20 0.37
PMP22 Q01453 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
POLB P06746 1/20 0.37
KMT2A Q03164 2/20 0.36
FFAR2 O15552 1/20 0.36
MAPT P10636 1/20 0.35
MEN1 O00255 1/20 0.35
GAA P10253 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PPARG P37231 4/20 0.35
EPHX2 P34913 1/20 0.35
PPARA Q07869 3/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1127319 0.93 MAPT (0.39) GPR119KMT2AMAPTMEN1GAA
SCHEMBL1127320 0.89 TSHR (0.44) KMT2AMAPTMEN1GAAPPARG
SCHEMBL1129447 0.88 ALDH1A1 (0.39) NPSR1KMT2AMAPTMEN1GAA
SCHEMBL1127442 0.87 KDM4E (0.37) KMT2AMAPTMEN1GAASMN1; SMN2
SCHEMBL4281414 0.87 MME (0.38) MMEKMT2AMAPTMEN1GAA
SCHEMBL1127497 0.85 ALDH1A1 (0.36) MMEKMT2AMAPTMEN1GAA
SCHEMBL1127310 0.83 KMT2A (0.36) MMELMNAKMT2AMAPTMEN1
SCHEMBL1127832 0.83 TAAR1 (0.40) MMEKMT2APPARGPPARAALDH1A1
SCHEMBL1127390 0.82 KMT2A (0.48) MMECNR1CNR2GPR119BLM
SCHEMBL1127255 0.81 ALDH1A1 (0.43) LMNANPSR1POLBKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2283002-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION Intermune, Inc. (US) 2011-02-16 EP disclosed
WO-2009134616-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-11-05 WO disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication EIF2AK2, HAVCR2, HDGF MME 377/4885CNR1 1204/4885CNR2 2268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.